CN109078173A - 一种包含自体胶原蛋白的愈合剂及其应用 - Google Patents
一种包含自体胶原蛋白的愈合剂及其应用 Download PDFInfo
- Publication number
- CN109078173A CN109078173A CN201810978471.8A CN201810978471A CN109078173A CN 109078173 A CN109078173 A CN 109078173A CN 201810978471 A CN201810978471 A CN 201810978471A CN 109078173 A CN109078173 A CN 109078173A
- Authority
- CN
- China
- Prior art keywords
- consolidant
- autologous collagen
- collagen albumen
- layer
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 57
- 108010035532 Collagen Proteins 0.000 title claims abstract description 57
- 229920001436 collagen Polymers 0.000 title claims abstract description 50
- 239000011230 binding agent Substances 0.000 claims abstract description 18
- 239000011718 vitamin C Substances 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 14
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 14
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 14
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 14
- 239000011570 nicotinamide Substances 0.000 claims abstract description 14
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 14
- 239000008367 deionised water Substances 0.000 claims abstract description 11
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 11
- 230000029663 wound healing Effects 0.000 claims abstract description 10
- 210000004369 blood Anatomy 0.000 claims description 45
- 239000008280 blood Substances 0.000 claims description 45
- 210000003743 erythrocyte Anatomy 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 210000000744 eyelid Anatomy 0.000 claims description 13
- 238000003860 storage Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 8
- 238000004587 chromatography analysis Methods 0.000 claims description 7
- 238000011026 diafiltration Methods 0.000 claims description 7
- 230000008676 import Effects 0.000 claims description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 4
- 229940116977 epidermal growth factor Drugs 0.000 claims description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 102000013275 Somatomedins Human genes 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 231100000241 scar Toxicity 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- 230000008439 repair process Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 210000001519 tissue Anatomy 0.000 abstract description 4
- 239000000806 elastomer Substances 0.000 abstract description 3
- 229920001971 elastomer Polymers 0.000 abstract description 3
- 230000004936 stimulating effect Effects 0.000 abstract description 3
- 208000037656 Respiratory Sounds Diseases 0.000 abstract description 2
- 230000004913 activation Effects 0.000 abstract description 2
- 210000002808 connective tissue Anatomy 0.000 abstract description 2
- 206010020718 hyperplasia Diseases 0.000 abstract description 2
- 230000036560 skin regeneration Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 14
- 229920001661 Chitosan Polymers 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000002980 postoperative effect Effects 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 102000003967 Fibroblast growth factor 5 Human genes 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003519 biomedical and dental material Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000009400 out breeding Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000000457 tarsus Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种包含自体胶原蛋白的愈合剂,按重量百分含量计,所述愈合剂包括自体胶原蛋白20‑35%、烟酰胺15‑20%、细胞生长因子5‑10%、左旋维生素C 2‑8%、透明质酸2‑6%、粘结剂1‑5%、余量为去离子水。本发明还公开了一种包含自体胶原蛋白的愈合剂的应用。本发明各组分配合使用协同增效,具有刺激活性细胞,激活皮肤组织,补充胶原蛋白,重建弹性纤维,修复受损细胞,快速更新结缔组织,深层滋养肌肤,改善皮肤的裂纹症状,增强皮肤再生功能,修复激活受损细胞组织从而逐渐修复疤痕的功能。既可以促进伤口愈合、减小疤痕的形成,同时对于已经形成的疤痕具有良好的修复作用,有效促进伤口愈合、有效抑制疤痕、癒痕增生,实现伤口愈合而不留疤痕的疗效。
Description
技术领域
本发明涉及生物医用材料技术领域,具体涉及一种包含自体胶原蛋白的愈合剂及其应用。
背景技术
随着现代社会的发展,中国已经成了整形大国。眼睛是情感交流的窗口,眼部的形态对面部的美感起到至关重要的作用,重睑术是最常见也是最受欢迎的美容手术之一。
重睑术俗称双眼皮成形术,是在整形外科中常见的一种手术。其原理是通过手术的方法,使睑板前的皮肤与上睑提肌腱膜的纤维在睑板上缘形成牢固的粘连,这样在上睑提肌做上提运动时,形成重睑皱褶,即是双眼皮。不同的重睑病例,手术方法也不同,一般分为切开法和埋线法两大类。传统的切开法进行手术,术后患者眼部会长时间的肿胀,不良反应发生率较高,不利于患者恢复;埋线法手术虽然对患者眼部创伤小,但术后保持时间却较短。
切口疼痛、渗血、肿胀,甚至切口感染,导致伤口疤痕的形成是重睑术后常见的问题。有鉴于此,特提出本发明。
发明内容
为了解决现有技术存在的问题,本发明实施例的目的在于提供一种包含自体胶原蛋白的愈合剂及其应用。本发明的愈合剂是外敷试剂,使用方便,在促进伤口恢复方面效果确切。
为实现上述目的,本发明实施例的第一方面提供了一种包含自体胶原蛋白的愈合剂,按重量百分含量计,所述愈合剂包括自体胶原蛋白20-35%、烟酰胺15-20%、细胞生长因子5-10%、左旋维生素C 2-8%、透明质酸2-6%、粘结剂1-5%、余量为去离子水。
进一步地,按重量百分含量计,所述愈合剂包括自体胶原蛋白25-30%、烟酰胺16-18%、细胞生长因子8-10%、左旋维生素C 5-8%、透明质酸2-5%、粘结剂3-5%、余量为去离子水。
进一步地,所述细胞生长因子包括成纤维细胞生长因子、表皮生长因子、类胰岛素生长因子中的一种或多种。
进一步地,所述粘结剂包括壳聚糖和羧甲基纤维素钠,其重量比为1:1-3。
进一步地,所述自体胶原蛋白的制备方法为:通过采血针对人体进行采血,血液经首次离心后进入全血分离器,并在全血分离器内进行二次离心,全血离心分为三层,自上而下依次为血浆层、白膜层和红细胞层,将血浆层、白膜层和红细胞层的液体分别通过导管导入不同的储存单元分开存放,由储存单元取出适量血浆层和白膜层液体按比例混合,并经层析单元进行初步纯化、透滤单元进一步纯化即得所需的自体胶原蛋白。
进一步地,所述愈合剂的制备方法为:按配比称取各组分,在去离子水中依次加入自体胶原蛋白、烟酰胺、细胞生长因子、左旋维生素C、透明质酸和粘结剂,分散均匀即可。
本发明的第二方面提供了一种上述的包含自体胶原蛋白的愈合剂在治疗术后伤口中的应用。
进一步地,所述愈合剂在治疗重睑术后伤口愈合中的应用。
本发明实施例中的各组分的作用:
自体胶原蛋白由人体静脉血提取的富集大量血小板和胶原蛋白的自体胶原蛋白制成,血液经离心分为三层,血浆层主要包含血浆、水、蛋白质、盐类和各种离子等,白膜层主要包括富含血小板区、富含淋巴细胞区、富含单核细胞区和富含粒细胞区,红细胞层可简单分为年轻红细胞和正常红细胞,提取的血浆层和白膜层混合液中含有大量胶原蛋白,同时富含血小板和各种生长因子,进入真皮浅层后,可刺激胶原蛋白、弹性纤维、胶质等的产生,促使组织再生。
烟酰胺:又名维生素PP,为辅酶I和辅酶II的组成部分,在生物氧化呼吸链中起着递氢的作用,烟酰胺可促进生物氧化过程和组织新陈代谢,对维持正常组织特别是皮肤的完整性具有重要作用,有助于患处的皮肤光滑平整,不留疤痕。
细胞生长因子:是一种多功能强力细胞因子,对促进成纤维细胞的代谢和胶原蛋白的形成发挥着重要功能。细胞生长因子能促进皮肤组织的生长繁殖,它通过与细胞表面特异受体结合,调控皮肤上皮,内皮和基质细胞的分裂、繁殖和生长分化,促进细胞代谢,增强氧化作用;能促进与皮肤损伤有关细胞的迅速生长繁殖,并调节细胞间基质的合成、分泌及分解;能促进角质层细胞的再生,加速皮肤角质层和基质层的修复,促进人体皮肤细胞的生长;能增强皮肤细胞的蛋白质的合成和细胞代谢,具有延缓皮肤细胞衰老、促进表皮细胞的修复和生长作用,使皮肤光滑丰润。
左旋维生素C:是唯一可直接被人体肌肤所吸收的维生素C形式。其能抑制酪胺酸酶及还原黑色素,并淡化已形成的斑点,抑制黑色素形成;左旋维生素C是制造胶原蛋白必须成分,能促进胶原蛋白合成减少细纹;左旋维生素C能有效中和自由基,改善肌肤纹路,还原受损肌肤,让皮肤紧实有弹性。
透明质酸:又称糖醛酸、玻尿酸,广泛存在于人体各部位,其中皮肤中即含有大量的透明质酸,其具有保温、嫩肤、去皱和防衰老的效果,同时透明质酸还是有效的透皮吸收促进剂,其可有效促进营养成分的透皮吸收,因此,广泛应用于各类化妆品中。
甲壳素是存在于自然界中的惟一一种带阳离子能被生物降解的分布极其广泛的高分子材料,大量存在于昆虫、甲壳纲动物外壳及真菌的细胞壁中,是地球上仅次于纤维素的第二大可再生资源,但不溶于水及有机溶剂,很难被人体利用。其脱乙酰基所得产物称为壳聚糖,则能被人体吸收利用。这类多糖既可生物合成,又可生物降解,与动物的器官组织及细胞有良好的生物相容性,无毒,降解过程中产生的低分子寡聚糖在体内不积累,几乎无免疫原性。经研究一致认为壳聚糖不仅具有天然抗菌性能,而且抗菌谱广。
羧甲基纤维素钠是一种生物相容性良好的纤维素衍生物,其水溶液具有一定的粘性,不仅可用作片剂的黏合剂,而且还可用作注射剂的助悬剂。
本发明实施例具有如下优点:
本发明各组分配合使用协同增效,具有刺激活性细胞,激活皮肤组织,补充胶原蛋白,重建弹性纤维,修复受损细胞,快速更新结缔组织,深层滋养肌肤,改善皮肤的裂纹症状,增强皮肤再生功能,修复激活受损细胞组织从而逐渐修复疤痕的功能。既可以促进伤口愈合、减小疤痕的形成,同时对于已经形成的疤痕具有良好的修复作用,有效促进伤口愈合、有效抑制疤痕、癒痕增生,实现伤口愈合而不留疤痕的疗效。
本发明的愈合剂不含任何刺激性成分,无毒副作用,具有安全性好且使用便利的优点。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。下文中,%表示重量百分含量。
实施例1
本实施例的包含自体胶原蛋白的愈合剂的制备方法:在去离子水40%中依次加入自体胶原蛋白26%、烟酰胺18%、成纤维细胞生长因子5%、左旋维生素C 4%、透明质酸5%、粘结剂2%,分散均匀即可。
其中,粘结剂包括壳聚糖和羧甲基纤维素钠,其重量比为1:1。
自体胶原蛋白的制备方法为:通过采血针对人体进行采血,血液经首次离心后进入全血分离器,并在全血分离器内进行二次离心,全血离心分为三层,自上而下依次为血浆层、白膜层和红细胞层,将血浆层、白膜层和红细胞层的液体分别通过导管导入不同的储存单元分开存放,由储存单元取出适量血浆层和白膜层液体按1:1混合,并经层析单元进行初步纯化、透滤单元进一步纯化即得所需的自体胶原蛋白。
实施例2
本实施例的包含自体胶原蛋白的愈合剂的制备方法:在去离子水37%中依次加入自体胶原蛋白32%、烟酰胺15%、表皮生长因子8%、左旋维生素C 2%、透明质酸2%、粘结剂4%,分散均匀即可。
其中,粘结剂包括壳聚糖和羧甲基纤维素钠,其重量比为1:2.5。
自体胶原蛋白的制备方法为:通过采血针对人体进行采血,血液经首次离心后进入全血分离器,并在全血分离器内进行二次离心,全血离心分为三层,自上而下依次为血浆层、白膜层和红细胞层,将血浆层、白膜层和红细胞层的液体分别通过导管导入不同的储存单元分开存放,由储存单元取出适量血浆层和白膜层液体按1:1混合,并经层析单元进行初步纯化、透滤单元进一步纯化即得所需的自体胶原蛋白。
实施例3
本实施例的包含自体胶原蛋白的愈合剂的制备方法:在去离子水35%中依次加入自体胶原蛋白22%、烟酰胺20%、纤维细胞生长因子5%、表皮生长因子5%、左旋维生素C6%、透明质酸2%、粘结剂5%,分散均匀即可。
其中,粘结剂包括壳聚糖和羧甲基纤维素钠,其重量比为1:3。
自体胶原蛋白的制备方法为:通过采血针对人体进行采血,血液经首次离心后进入全血分离器,并在全血分离器内进行二次离心,全血离心分为三层,自上而下依次为血浆层、白膜层和红细胞层,将血浆层、白膜层和红细胞层的液体分别通过导管导入不同的储存单元分开存放,由储存单元取出适量血浆层和白膜层液体按1:1混合,并经层析单元进行初步纯化、透滤单元进一步纯化即得所需的自体胶原蛋白。
实施例4
本实施例的包含自体胶原蛋白的愈合剂的制备方法:在去离子水40%中依次加入自体胶原蛋白35%、烟酰胺15%、类胰岛素生长因子5%、左旋维生素C 2%、透明质酸2%、粘结剂1%,分散均匀即可。
其中,粘结剂包括壳聚糖和羧甲基纤维素钠,其重量比为1:2。
自体胶原蛋白的制备方法为:通过采血针对人体进行采血,血液经首次离心后进入全血分离器,并在全血分离器内进行二次离心,全血离心分为三层,自上而下依次为血浆层、白膜层和红细胞层,将血浆层、白膜层和红细胞层的液体分别通过导管导入不同的储存单元分开存放,由储存单元取出适量血浆层和白膜层液体按1:1混合,并经层析单元进行初步纯化、透滤单元进一步纯化即得所需的自体胶原蛋白。
实施例5
本实施例的包含自体胶原蛋白的愈合剂的制备方法:在去离子水34%中依次加入自体胶原蛋白30%、烟酰胺18%、维细胞生长因子5%、左旋维生素C 8%、透明质酸2%、粘结剂3%,分散均匀即可。
其中,粘结剂包括壳聚糖和羧甲基纤维素钠,其重量比为1:1.5。
自体胶原蛋白的制备方法为:通过采血针对人体进行采血,血液经首次离心后进入全血分离器,并在全血分离器内进行二次离心,全血离心分为三层,自上而下依次为血浆层、白膜层和红细胞层,将血浆层、白膜层和红细胞层的液体分别通过导管导入不同的储存单元分开存放,由储存单元取出适量血浆层和白膜层液体按1:1混合,并经层析单元进行初步纯化、透滤单元进一步纯化即得所需的自体胶原蛋白。
试验例
为了说明本发明的愈合剂对重睑术后伤口愈合具有良好的恢复作用,本发明进行了下列疗效试验。
1、一般资料
选取2016年6月-2017年6月在本机构自愿接受本次试验的60例患者作为研究对象,所有患者健康状况良好,无其他系统性疾病,试验前均签订知情同意书。60例患者均曾行双侧切开法重睑成形术。将患者随机分为试验1-5组和对照组,每组均为10例。每组患者在性别、年龄、术式等一般资料差异均无统计学意义(P>0.05),具有可比性。
2、治疗方法
试验1-5组:分别将本发明实施例1-5制得的包含自体胶原蛋白的愈合剂涂抹于术后患者眼部伤口部位,稍加轻柔按摩即可。
对照组:对术后患者眼部伤口部位适当进行冰敷。
3、结果
受术者回访时,令其就重睑线、术后淤青、术后肿胀、伤口愈合时间、切口瘢痕明显程度满意程度进行评价,评价分为满意、基本满意和不满意。术后随访4-12个月,试验1-5组共50例患者满意人数共45人、基本满意3人,不满意2人,满意度达到90%以上,对照组10例患者满意人数为4人,基本满意1人,不满意5人,满意度为50%。
结果表明,本发明实施例的愈合剂能明显减少切开法重睑术中出血、术后的淤青,加快术后水肿的恢复,缩短受术者出现满意的重睑线的时间。
虽然,上文中已经用一般性说明及具体实施例对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (8)
1.一种包含自体胶原蛋白的愈合剂,其特征在于,按重量百分含量计,所述愈合剂包括自体胶原蛋白20-35%、烟酰胺15-20%、细胞生长因子5-10%、左旋维生素C 2-8%、透明质酸2-6%、粘结剂1-5%、余量为去离子水。
2.根据权利要求1所述的包含自体胶原蛋白的愈合剂,其特征在于,按重量百分含量计,所述愈合剂包括自体胶原蛋白25-30%、烟酰胺16-18%、细胞生长因子8-10%、左旋维生素C 5-8%、透明质酸2-5%、粘结剂3-5%、余量为去离子水。
3.根据权利要求1所述的包含自体胶原蛋白的愈合剂,其特征在于,所述细胞生长因子包括成纤维细胞生长因子、表皮生长因子、类胰岛素生长因子中的一种或多种。
4.根据权利要求1所述的包含自体胶原蛋白的愈合剂,其特征在于,所述粘结剂包括壳聚糖和羧甲基纤维素钠,其重量比为1:1-3。
5.根据权利要求1所述的包含自体胶原蛋白的愈合剂,其特征在于,所述自体胶原蛋白的制备方法为:通过采血针对人体进行采血,血液经首次离心后进入全血分离器,并在全血分离器内进行二次离心,全血离心分为三层,自上而下依次为血浆层、白膜层和红细胞层,将血浆层、白膜层和红细胞层的液体分别通过导管导入不同的储存单元分开存放,由储存单元取出适量血浆层和白膜层液体按比例混合,并经层析单元进行初步纯化、透滤单元进一步纯化即得所需的自体胶原蛋白。
6.根据权利要求1所述的包含自体胶原蛋白的愈合剂,其特征在于,所述愈合剂的制备方法为:按配比称取各组分,在去离子水中依次加入自体胶原蛋白、烟酰胺、细胞生长因子、左旋维生素C、透明质酸和粘结剂,分散均匀即可。
7.一种权利要求1所述的包含自体胶原蛋白的愈合剂在治疗术后伤口愈合中的应用。
8.根据权利要求7所述的应用,其特征在于,所述愈合剂在治疗重睑术后伤口愈合中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810978471.8A CN109078173A (zh) | 2018-08-27 | 2018-08-27 | 一种包含自体胶原蛋白的愈合剂及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810978471.8A CN109078173A (zh) | 2018-08-27 | 2018-08-27 | 一种包含自体胶原蛋白的愈合剂及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109078173A true CN109078173A (zh) | 2018-12-25 |
Family
ID=64794750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810978471.8A Withdrawn CN109078173A (zh) | 2018-08-27 | 2018-08-27 | 一种包含自体胶原蛋白的愈合剂及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109078173A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111110623A (zh) * | 2019-06-28 | 2020-05-08 | 青岛华澳现代医疗美容有限公司 | 自体修复小小针营养液配方 |
CN112263506A (zh) * | 2020-11-11 | 2021-01-26 | 杭州壹美汇医疗美容技术有限公司 | 一种自体胶原蛋白再生修复技术及祛皱的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090221985A1 (en) * | 2005-10-19 | 2009-09-03 | Shmuel Bukshpan | System for iontophoretic transdermal delivery of polymeric agents and methods of use thereof |
CN104491944A (zh) * | 2014-11-19 | 2015-04-08 | 沈阳优吉诺生物科技有限公司 | 一种血浆的提取装置及其提取方法 |
CN108341865A (zh) * | 2018-05-18 | 2018-07-31 | 白晋 | 一种新型的制备胶原蛋白的设备以及方法 |
-
2018
- 2018-08-27 CN CN201810978471.8A patent/CN109078173A/zh not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090221985A1 (en) * | 2005-10-19 | 2009-09-03 | Shmuel Bukshpan | System for iontophoretic transdermal delivery of polymeric agents and methods of use thereof |
CN104491944A (zh) * | 2014-11-19 | 2015-04-08 | 沈阳优吉诺生物科技有限公司 | 一种血浆的提取装置及其提取方法 |
CN108341865A (zh) * | 2018-05-18 | 2018-07-31 | 白晋 | 一种新型的制备胶原蛋白的设备以及方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111110623A (zh) * | 2019-06-28 | 2020-05-08 | 青岛华澳现代医疗美容有限公司 | 自体修复小小针营养液配方 |
CN112263506A (zh) * | 2020-11-11 | 2021-01-26 | 杭州壹美汇医疗美容技术有限公司 | 一种自体胶原蛋白再生修复技术及祛皱的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104587518B (zh) | 一种透明质酸敷料及其制备方法 | |
CN105125476B (zh) | 一种抗皱精华液及其制备方法 | |
CN114470314B (zh) | 一种重组人源化胶原蛋白凝胶敷料及其制备方法和应用 | |
CN101791283B (zh) | 一种可消除妊娠纹和疤痕的化妆品 | |
US8071106B2 (en) | Topical formulation containing latex of fraction thereof, and cosmetic treatment method | |
CN108578747A (zh) | 一种梯度透明质酸敷料及其制备方法 | |
JPH09507144A (ja) | 膜 | |
CN111110623A (zh) | 自体修复小小针营养液配方 | |
CN107184961A (zh) | 一种活性细胞修复剂及其制备方法 | |
CN108686255B (zh) | 一种预防疤痕形成的生物敷料及其制备方法 | |
CN113368027A (zh) | 一种自体胶原蛋白水光针及其制备方法 | |
CN105012228A (zh) | 防止疤痕形成及早期修复的玻尿酸硅凝胶组合物及制备方法 | |
CN104921983A (zh) | 一种孕妇妊娠纹医用生物修复敷料及其制备方法 | |
CN109078173A (zh) | 一种包含自体胶原蛋白的愈合剂及其应用 | |
CN108743921A (zh) | 一种预防疤痕形成的修复液及其制备方法和应用 | |
CN109731126A (zh) | 一种具有修复皮肤功能的生物敷料及其制备方法 | |
CN109771322A (zh) | 人干细胞因子皮肤修复组合物及其在护肤品中的应用 | |
CN102188362A (zh) | 一种用于自体皮肤表皮层屏障重建的自体全血匀浆复合物及其制备方法 | |
CN105749333B (zh) | 一种透明质酸医用敷料及其制备方法 | |
CN108785843A (zh) | 一种美容方法 | |
CN106344435A (zh) | 消除妊娠纹的护肤膏 | |
CN106963727A (zh) | 包含玻尿酸和抗菌肽的硅凝胶祛疤修复产品及其制备方法 | |
US6086578A (en) | Method for skin rejuvenation | |
CN113521258A (zh) | 一种改善衰老的组织注射液 | |
CN108744024A (zh) | 一种复配防疤痕液剂生物敷料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181225 |
|
WW01 | Invention patent application withdrawn after publication |